RhumbLine Advisers’s Genetic Technologies Ltd. GENE Stock Holding History

RhumbLine Advisers’s Portfolio GENE Stock Details GENE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.03K	Hold	2,650	–	–	﹤0.01%	3939
2025 Q4	$2.03K	Hold	2,650	–	–	﹤0.01%	3992
2025 Q3	$2.03K	Sell	2,650 -690	-21%	-$528	﹤0.01%	3989
2025 Q2	$2.55K	Sell	3,340 -399	-11%	-$305	﹤0.01%	3972
2025 Q1	$697	Hold	3,739	–	–	﹤0.01%	4043
2024 Q4	$2.86K	Hold	3,739	–	–	﹤0.01%	4008
2024 Q3	$2.79K	Hold	3,739	–	–	﹤0.01%	4042
2024 Q2	$5.57K	Hold	3,739	–	–	﹤0.01%	4070
2024 Q1	$10.8K	Hold	3,739	–	–	﹤0.01%	3854
2023 Q4	$9.05K	Sell	3,739 -1	-0%	-$3	﹤0.01%	3880
2023 Q3	$14.4K	Hold	3,740	–	–	﹤0.01%	3824
2023 Q2	$15.6K	Buy	+3,740	New	+$18.5K	﹤0.01%	3856

RhumbLine Advisers's GENE Position: Q1 2026 in Review

RhumbLine Advisers held its Genetic Technologies Ltd. (GENE) position steady in Q1 2026 at 2,650 shares worth $2.03K. The position accounts for ﹤0.01% of the portfolio, ranked #3939.

RhumbLine Advisers first reported a position in GENE in Q2 2023 and has held it in 12 quarters since. The position peaked at $15.6K in Q2 2023. 1 fund tracked by Wall St. Rank holds GENE as of Q1 2026.

RhumbLine Advisers held 2,650 shares of Genetic Technologies Ltd. worth $2.03K as of Q1 2026.
RhumbLine Advisers left its Genetic Technologies Ltd. share count unchanged in Q1 2026.
Genetic Technologies Ltd. made up ﹤0.01% of RhumbLine Advisers's portfolio in Q1 2026, its #3939 holding.
RhumbLine Advisers first reported a position in Genetic Technologies Ltd. in Q2 2023 and has held it in 12 quarters since.
RhumbLine Advisers's Genetic Technologies Ltd. position peaked at $15.6K in Q2 2023.
1 fund tracked by Wall St. Rank held Genetic Technologies Ltd. as of Q1 2026.

Based on RhumbLine Advisers's 13F filing for Q1 2026, filed 12 May 2026.